USPTO Issues New Patent To Ryogen

Ryogen has been awarded a new patent titled ‘Isolated Genomic Polynucleotide Fragments from Chromosome 7’.

US patent No 7588915 has been issued by the US Patent and Trademark Office (USPTO), claims isolated genomic polynucleotide fragments that encode human adipocyte enhancer binding protein 1 (AEBP1), complementary polynucleotides, vectors and host cells containing these fragments and a method for obtaining AEBP1.

James Ryan, inventor and chief scientist of Ryogen, said: “The protein encoded by the claimed sequences is thought to play a role in diabetes and metabolic syndrome, obesity, inflammation, immune processes, osteopenia and atherogenesis,”

Valeria Poltorak, executive vice president of Ryogen, said: “The new patent is an important addition to Ryogen’s intellectual property portfolio. We are planning to offer this patent for licensing to make it widely available to researchers to facilitate the development of new diagnostic and treatment methods.”

Ryogen, headquartered in Suffern, New York, is a genomic start-up and a portfolio company of IP Holdings.